Through database analysis, we showed that high ZNF521 expression was significantly associated with poor survival outcomes in ovarian cancer, gastric cancer, colon adenocarcinoma, bladder cancer, lung squamous cell carcinoma, and thyroid cancer. Here, ZNF521 is linked to colon adenocarcinoma.